Avalo Therapeutics Files 8-K
Ticker: AVTX · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
Related Tickers: AVLO
TL;DR
AVLO filed an 8-K, likely containing routine updates. Keep an eye out for details.
AI Summary
On June 4, 2025, Avalo Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information related to "Other Events" and "Financial Statements and Exhibits." No specific material events or financial details were disclosed in the provided excerpt.
Why It Matters
This filing signals that Avalo Therapeutics is making a regulatory submission to the SEC, which could contain important updates about the company's operations or financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not, in this excerpt, disclose any new material information that would immediately impact risk.
Key Numbers
- 001-37590 — SEC File Number (Identifies the company's filing history with the SEC.)
- 45-0705648 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- June 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087 (address) — Principal executive offices
- Cerecor Inc. (company) — Former company name
FAQ
What specific "Other Events" are being reported by Avalo Therapeutics?
The provided excerpt does not specify the nature of the "Other Events" being reported; it only lists the category.
What "Financial Statements and Exhibits" are included in this 8-K filing?
The excerpt states that "Financial Statements and Exhibits" are part of the filing, but does not detail their content.
When was Avalo Therapeutics, Inc. formerly known as Cerecor Inc.?
The date of the name change from Cerecor Inc. to Avalo Therapeutics, Inc. was November 2, 2011.
What is Avalo Therapeutics' principal executive office address?
Avalo Therapeutics' principal executive offices are located at 1500 Liberty Ridge Drive, Suite 321, Wayne, Pennsylvania 19087.
What is the standard industrial classification for Avalo Therapeutics?
Avalo Therapeutics falls under the Standard Industrial Classification code 2834, which is for Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding Avalo Therapeutics, Inc. (AVTX).